A photo of Robert W. Frenck Jr.

Director, Vaccine Research Center

Executive Chair, Institutional Review Board (IRB)

Professor, UC Department of Pediatrics

513-636-4463

513-636-3959

Board Certified

Best Doctors logo

My Biography & Research

Biography

The research that I’m most interested in is developing vaccines to prevent infections. Vaccines are the most impressive public health measure to reduce the rates of disease. I was inspired to pursue this area of pediatric patient care because infections are still the leading cause of death among children worldwide. I believe that finding methods to reduce infections among children will greatly enhance children's lives and help them grow up into healthy, happy adults.

Vaccines have saved more lives and averted more diseases than any other remedy that exists in medicine. Distributing vaccines around the globe has eliminated smallpox and has nearly eliminated polio. Furthermore, new vaccines are likely to prevent new infections, such as Ebola and COVID-19.

I am Director of the Gamble Center for Clinical Research, where my colleagues and I assess new vaccines and agents designed to prevent infections. I’m also the principal investigator of the Vaccine Treatment and Evaluation Unit (VTEU), which is funded by the National Institutes of Health (NIH).

At the Cincinnati Children’s Hospital Medical Center, we are one of nine VTEU sites that exist in the United States. Our hospital was selected as a VTEU site due to our extensive history of excellence in vaccine testing.

My research has been published in various journals, including Clinical Infectious Diseases, Open Forum Infectious Diseases, Lancet Infectious Diseases, and the Journal of Clinical Rheumatology: Practical Reports on Rheumatic and Musculoskeletal Disease. I’m an acknowledged authority in infectious diseases and have authored more than 125 articles and book chapters.

Clinical Interests

Vaccine research; enteric diseases; travel medicine

Research Interests

Enteric diseases; vaccinology

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Infectious Diseases

Research Divisions

Infectious Diseases



Blog Posts

Ask the Expert: The COVID-19 Vaccine and Kids

BlogVaccines

Ask the Expert: The COVID-19 Vaccine and Kids

By Dr. Robert Frenck5/4/2021

COVID-19 Vaccine Development and Implementation

Infectious Diseases and Vaccines

COVID-19 Vaccine Development and Implementation

Robert W. Frenck Jr., MD2/1/2021

Physicians Advocate for COVID-19 Vaccine Trials in Kids

Infectious Diseases and Vaccines

Physicians Advocate for COVID-19 Vaccine Trials in Kids

Robert W. Frenck Jr., MD, Paul Spearman, MD9/18/2020

Top 6 Reasons Why Clinical Trials Are Important

BlogResearch and Discoveries

Top 6 Reasons Why Clinical Trials Are Important

By Dr. Robert Frenck11/27/2018

Reminder: Incoming 7th & 12th Graders Need Meningococcal Vaccine

BlogVaccines

Reminder: Incoming 7th & 12th Graders Need Meningococcal Vaccine

By Dr. Robert Frenck7/28/2016

Vaccines

BlogVaccines

Vaccines: Their Own Worst Enemy

By Dr. Robert Frenck9/5/2013

My Locations

My Education

BA: University of California at San Diego, San Diego, CA, 1977.

MD: University of Texas Medical School at Houston, Houston, TX, 1981.

Internship and Residency: US Naval Hospital, Bethesda, MD, 1981-1984.

Fellowship: Pediatric Infectious Diseases, University of Texas Medical School at Houston, Houston, TX, 1987-1990.

My Publications

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. Polack, FP; Thomas, SJ; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Perez, JL; Marc, GP; Moreira, ED; Zerbini, C; et al. The New England journal of medicine. 2020; 383:2603-2615.

Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. Walsh, EE; Frenck, RW; Falsey, AR; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Neuzil, K; Mulligan, MJ; Bailey, R; et al. The New England journal of medicine. 2020; 383:2439-2450.

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Mulligan, MJ; Lyke, KE; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Neuzil, K; Raabe, V; Bailey, R; Swanson, KA; et al. Nature. 2020; 586:589-593.

Immune response characterization after controlled infection with lyophilized shigella sonnei 53G. Clarkson, KA; Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Weerts, HP; Heaney, CD; McNeal, M; Detizio, K; Parker, S; et al. mSphere. 2020; 5.

Establishment of a controlled human infection model with a lyophilized strain of shigella sonnei 53G. Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Kaminski, RW; Clarkson, KA; McNeal, M; Lynen, A; Parker, S; Hoeper, A; et al. mSphere. 2020; 5.

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study. Walsh, EE; Frenck, R; Falsey, AR; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Neuzil, K; Mulligan, MJ; Bailey, R; et al. 2020.

Hospital-acquired pneumonia and ventilator-associated pneumonia in children: A prospective natural history and case-control study. Ericson, JE; McGuire, J; Michaels, MG; Schwarz, A; Frenck, R; Deville, JG; Agarwal, S; Bressler, AM; Gao, J; Spears, T; et al. The Pediatric Infectious Disease Journal. 2020; 39:658-664.

Hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Children. Ericson, JE; McGuire, J; Michaels, MG; Schwarz, A; Frenck, R; Deville, JG; Agarwal, S; Bressler, AM; Gao, J; Spears, T; et al. The Pediatric Infectious Disease Journal. 2020; 39:658-664.

Third human challenge trial conference, Oxford, United Kingdom, February 6–7, 2020, a meeting report. Pollard, AJ; Sauerwein, R; Baay, M; Neels, P; Balasingam, S; Bejon, P; Berthels, N; Bull, S; Catchpole, A; Chi, P; et al. (2020) Elsevier BV. 66:41-52.

Persistence of immune responses through 36 months in healthy adults after vaccination with a novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag). Creech, CB; Frenck, RW; Fiquet, A; Feldman, R; Kankam, MK; Pathirana, S; Baber, J; Radley, D; Cooper, D; Eiden, J; et al. Open Forum Infectious Diseases. 2020; 7.